Literature DB >> 19195323

Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.

Sophie Duraffour1, Solenne Vigne, Kurt Vermeire, Aude Garcel, Els Vanstreels, Dirk Daelemans, Guang Yang, Robert Jordan, Dennis E Hruby, Jean-Marc Crance, Daniel Garin, Graciela Andrei, Robert Snoeck.   

Abstract

BACKGROUND: ST-246 is a potent anti-orthopoxviral molecule targeting the F13L protein of vaccinia virus, which is involved in the wrapping of viruses. The discrepancy in sensitivities of several orthopoxviruses to ST-246 has raised questions about potential differences in their replicative cycles and/or the presence of another drug target.
METHODS: Density gradients were used to evaluate the differences between the viral cycles of vaccinia, cowpox and camelpox viruses. Also, to investigate if ST-246 inhibits a single target, we compared its activity to that of small interfering RNAs designed to silence the F13L gene (siF13Ls).
RESULTS: We showed that the spread of vaccinia virus involved both intracellular and extracellular enveloped viruses, whereas both cowpox and camelpox viruses seemed to propagate via non-enveloped intracellular forms and cell-associated viral particles. Although ST-246 exerted a clear antiviral activity by interfering with the egress of the virus from infected cells, we observed that cowpox and camelpox viruses, in contrast to vaccinia virus, could be directed towards a lytic cycle under ST-246 treatment. We specifically knocked down the F13L transcripts of vaccinia and camelpox viruses by > 85%, reduced virus progeny by 90% and showed that siF13Ls affect camelpox and vaccinia virus propagation differently. Flow cytometry data validated that ST-246 interfered with the activity of the F13L protein, whereas siF13Ls silenced the F13L gene.
CONCLUSIONS: Our observations support that vaccinia, cowpox and camelpox viruses exhibit different levels of sensitivity to ST-246 because of dissimilarities between their ways of propagation, and provide a better understanding of the mode of action of ST-246.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19195323

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535            Impact factor:   1.679


  9 in total

1.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Control of African swine fever virus replication by small interfering RNA targeting the A151R and VP72 genes.

Authors:  Djénéba Keita; Livio Heath; Emmanuel Albina
Journal:  Antivir Ther       Date:  2010

3.  Historical perspectives in the development of antiviral agents against poxviruses.

Authors:  Erik De Clercq
Journal:  Viruses       Date:  2010-06-14       Impact factor: 5.818

4.  Study of camelpox virus pathogenesis in athymic nude mice.

Authors:  Sophie Duraffour; Patrick Matthys; Joost J van den Oord; Tim De Schutter; Tania Mitera; Robert Snoeck; Graciela Andrei
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

5.  Polycyclic N-benzamido imides with potent activity against vaccinia virus.

Authors:  Eva Torres; María D Duque; Pelayo Camps; Lieve Naesens; Teresa Calvet; Mercè Font-Bardia; Santiago Vázquez
Journal:  ChemMedChem       Date:  2010-12-03       Impact factor: 3.540

Review 6.  Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes.

Authors:  Mike Bray; Michele Di Mascio; Fabian de Kok-Mercado; Daniel J Mollura; Elaine Jagoda
Journal:  Antiviral Res       Date:  2010-08-13       Impact factor: 5.970

Review 7.  Why do poxviruses still matter?

Authors:  Zhilong Yang; Mark Gray; Lake Winter
Journal:  Cell Biosci       Date:  2021-05-22       Impact factor: 7.133

8.  Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals.

Authors:  Sophie Duraffour; Barbara Mertens; Hermann Meyer; Joost J van den Oord; Tania Mitera; Patrick Matthys; Robert Snoeck; Graciela Andrei
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

9.  ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.

Authors:  Sophie Duraffour; María M Lorenzo; Gudrun Zöller; Dimitri Topalis; Doug Grosenbach; Dennis E Hruby; Graciela Andrei; Rafael Blasco; Hermann Meyer; Robert Snoeck
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.